[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581950":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":140,"collaborators":10,"id":142,"slug":143,"hasResults":144,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":10,"eligibilityCriteria":148,"healthyVolunteers":144,"sex":149,"minAge":10,"maxAge":150,"enrollmentInfo":151,"targetDuration":10,"studyType":154,"phases":10,"briefSummary":155,"conditions":156,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},{"fullName":5,"class":6},"Meyer Children's Hospital IRCCS","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cases",null,"Patients aged \\\u003C1 years hospitalized with confirmed bronchiolitis",[13],"Drug: Nirsevimab",{"label":15,"type":10,"description":16,"interventionNames":17},"Controls","Patients aged \\\u003C1 years hospitalized for condition other than confirmed bronchiolitis",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","Nirsevimab","Evaluation of drug exposure in cases and controls",[9,15],[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Giuseppe Indolfi","CONTACT","+3905556621","giuseppe.indolfi@meyer.it",[31,49,64,78,86,98,112,126],{"facility":32,"status":33,"city":34,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"SOC Pediatria Ospedale San Donato","RECRUITING","Arezzo","52100","Italy","IT",{"type":39,"coordinates":40},"Point",[41,42],11.88068,43.46276,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":47,"phoneExt":10,"email":48},"Martini Marco, MD","+390575 255531","marco.martini@uslsudest.toscana.it",{"facility":50,"status":33,"city":51,"state":52,"zip":53,"country":36,"countryCode":37,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"SOC Pediatria Ospedale Santa Maria Annunziata","Bagno a Ripoli","Firenze","50012",{"type":39,"coordinates":55},[56,57],11.32252,43.75115,{"lat":57,"lon":56},[60],{"name":61,"role":27,"phone":62,"phoneExt":10,"email":63},"Mirri Gianpaolo, MD","+39055 6936436","gianpaolo.mirri@uslcentro.toscana.it",{"facility":65,"status":33,"city":66,"state":52,"zip":67,"country":36,"countryCode":37,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"SOC Neonatologia e Terapia Intensiva Neonatale, Ospedale San Giovanni Di Dio","Florence","50134",{"type":39,"coordinates":69},[70,71],11.24626,43.77925,{"lat":71,"lon":70},[74],{"name":75,"role":27,"phone":76,"phoneExt":10,"email":77},"Lori Ilaria, MD","+39055 6932201","ilaria.lori@uslcentro.toscana.it",{"facility":5,"status":33,"city":66,"state":36,"zip":79,"country":36,"countryCode":37,"cosmosGeoPoint":80,"geoPoint":82,"contacts":83},"50139",{"type":39,"coordinates":81},[70,71],{"lat":71,"lon":70},[84],{"name":26,"role":85,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":87,"status":33,"city":88,"state":36,"zip":89,"country":36,"countryCode":37,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Azienda Ospedaliero Universitaria Pisana","Pisa","56123",{"type":39,"coordinates":91},[92,93],10.4036,43.70853,{"lat":93,"lon":92},[96],{"name":97,"role":85,"phone":10,"phoneExt":10,"email":10},"Diego Peroni",{"facility":99,"status":33,"city":100,"state":100,"zip":101,"country":36,"countryCode":37,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"SOC Pediatria e Neonatologia Ospedale San Jacopo","Pistoia","51100",{"type":39,"coordinates":103},[104,105],10.92365,43.93064,{"lat":105,"lon":104},[108],{"name":109,"role":27,"phone":110,"phoneExt":10,"email":111},"Agostiniani RIno, MD","+390573 351122 - 0573 351121","rino1.agostiniani@uslcentro.toscana.it",{"facility":113,"status":33,"city":114,"state":114,"zip":115,"country":36,"countryCode":37,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"SOC Pediatria e Neonatologia Ospedale Santo Stefano","Prato","59100",{"type":39,"coordinates":117},[118,119],11.09699,43.8805,{"lat":119,"lon":118},[122],{"name":123,"role":27,"phone":124,"phoneExt":10,"email":125},"Vasarri Pierluigi, MD","+390574802367-2350","pierluigi.vasarri@uslcentro.toscana.it",{"facility":127,"status":33,"city":128,"state":128,"zip":129,"country":36,"countryCode":37,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"SOC Pediatria AOU Senese","Siena","53100",{"type":39,"coordinates":131},[132,133],11.33064,43.31822,{"lat":133,"lon":132},[136],{"name":137,"role":27,"phone":138,"phoneExt":10,"email":139},"Grosso Salvatore, Professor, MD","+300577 585292","salvatore.grosso@uslcentro.toscana.it",{"type":85,"investigatorFullName":26,"investigatorTitle":141,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"MD","100581950","evaluation-of-the-effect-of-nirsevimab-on-hospitalizations-due-to-rsv-infection-in-infants-under-one-year-of-age-100581950",false,"NCT06856967","Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.","Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age: A Case-Control Study","Inclusion Criteria:\n\nCase patients\n\n* Age \\\u003C12 months\n* Diagnosis of LRTI (i.e., bronchiolitis and\u002For pneumonia) at admission\n* Positive RSV PCR on nasopharyngeal swab Control patients\n* Age \\\u003C12 months\n* Diagnosis of LRTI (i.e., bronchiolitis and\u002For pneumonia) at admission\n* Hospitalized for conditions other than respiratory infections\n\nExclusion Criteria:\n\n* Parental refusal\n* Previous immunization with Palivizumab\n* Previous maternal RSV vaccine immunization during pregnancy","ALL","12 Months",{"count":152,"type":153},138,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the impact of Nirsevimab, a monoclonal antibody used for RSV prophylaxis, on reducing RSV- related hospitalizations. It will be conducted at 8 pediatric departments in Tuscany, Italy. First, a matched case-control study investigates the real-world effectiveness of Nirsevimab in preventing RSV-related lower respiratory tract infection (LRTI) hospitalizations during the RSV epidemic season 2024-2025. Second, a descriptive study examines how the Nirsevimab immunization campaign affects RSV epidemiology, focusing on patients' age, comorbidities, infection severity, and clinical outcomes. The findings aim to optimize RSV prevention strategies and inform public health policies.",[157],"Respiratory Synctial Virus Infections","2025-03-05",{"date":160,"type":161},"2025-03-10","ACTUAL",{"date":163,"type":161},"2024-12-04",{"date":165,"type":153},"2025-04",{"name":5,"class":6},8]